Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Actuarial Post Awards 2025 Vote Now
Welcome to the 2025 Actuarial Post Awards. We would like to announce, that after yet another record number of nominations for the Actuarial Post Award
PRAs life insurance stress test
Prudential Regulation Authority’s (PRA) LIST25 stress test assesses UK bulk purchase annuity insurers' resilience under severe scenarios, with fi
Balancing higher pension costs with retention
With the government re-establishing the Pensions Commission, attention is turning again to auto-enrolment. Minimum contributions have been stuck for y

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.